Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma

BACKGROUND: Survival heterogeneity and limited trial follow-up present challenges for estimating lifetime benefits of oncology therapies. This study used CheckMate 067 (NCT01844505) extended follow-up data to assess the predictive accuracy of standard parametric and flexible models in estimating the...

Descripción completa

Detalles Bibliográficos
Autores principales: Federico Paly, Victoria, Kurt, Murat, Zhang, Lirong, Butler, Marcus O., Michielin, Olivier, Amadi, Adenike, Hernlund, Emma, Johnson, Helen M., Kotapati, Srividya, Moshyk, Andriy, Borrill, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958523/
https://www.ncbi.nlm.nih.gov/pubmed/35356551
http://dx.doi.org/10.1177/23814683221089659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958523/
https://www.ncbi.nlm.nih.gov/pubmed/35356551
http://dx.doi.org/10.1177/23814683221089659

Ejemplares similares